These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25188297)

  • 1. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results.
    Bradley JM; Koker P; Deng Q; Moroni-Zentgraf P; Ratjen F; Geller DE; Elborn JS;
    PLoS One; 2014; 9(9):e106195. PubMed ID: 25188297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.
    Ratjen F; Koker P; Geller DE; Langellier-Cocteaux B; Le Maulf F; Kattenbeck S; Moroni-Zentgraf P; Elborn JS;
    J Cyst Fibros; 2015 Sep; 14(5):608-14. PubMed ID: 25819269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
    Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
    Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
    Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
    Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
    Tang Y; Massey D; Zhong NS
    Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
    Ma J; Zhou Z; Tang Y; Zhong N
    Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
    Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.
    Bateman E; Singh D; Smith D; Disse B; Towse L; Massey D; Blatchford J; Pavia D; Hodder R
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():197-208. PubMed ID: 20714373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
    Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
    J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C; Chong J; Poole P
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.
    Kerstjens HA; Disse B; Schröder-Babo W; Bantje TA; Gahlemann M; Sigmund R; Engel M; van Noord JA
    J Allergy Clin Immunol; 2011 Aug; 128(2):308-14. PubMed ID: 21636120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan.
    Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC
    J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
    Bateman ED; Tashkin D; Siafakas N; Dahl R; Towse L; Massey D; Pavia D; Zhong NS
    Respir Med; 2010 Oct; 104(10):1460-72. PubMed ID: 20620037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.